Search research articles
Contact Us
Filters
Showing results (11-20 of 26) with videos related to
Page
of 3
Sort By:
Journal of Hematology & Oncology
|
June 7, 2022
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
David Kegyes, Catalin Constantinescu, Louise Vrancken, et al.
Critical Reviews in Oncology/Hematology
|
March 13, 2026
Integrating venetoclax-based targeted and/or immune therapies for chronic lymphocytic leukemia
David Kegyes, Ximena Muresan, Anamaria Bancos, et al.
Molecular Cancer Therapeutics
|
January 2, 2026
Proteolysis targeting chimeric-based technology in myeloma and lymphoma
Adrian Bogdan Tigu, Andrei Ivancuta, Ciprian Tomuleasa, et al.
Best Practice & Research. Clinical Haematology
|
September 7, 2025
Adoptive cellular therapies in multiple myeloma
David Kegyes, Bogdan Borlea, Marc Damian, et al.
Blood Reviews
|
June 8, 2023
Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma
David Kegyes, Diana Gulei, Rares Drula, et al.
Diagnostics (Basel, Switzerland)
|
September 28, 2024
"Lazarus Response" When Feto-Maternal Microchimerism Kicks in: Spontaneous Remission in Refractory Primary Mediastinal B Cell Lymphoma Following Twin Pregnancy
Radu Andrei Tomai, Sabina Iluta, Adrian Bogdan Tigu, et al.
Best Practice & Research. Clinical Haematology
|
September 7, 2025
Adoptive cellular therapies in non-Hodgkin lymphomas
David Kegyes, Bogdan Borlea, Marc Damian, et al.
Journal of Cellular and Molecular Medicine
|
February 10, 2026
Snapshot Look at Castleman Disease
Ciprian Jitaru, Natalia Zlampa, Delia Dima, et al.
Journal of Cellular and Molecular Medicine
|
March 5, 2025
SERS-Based Assessment of DNA Methylation for the Evaluation of Measurable Residual Disease in Acute Promyelocytic Leukaemia
Anamaria Bancos, Stefania D Iancu, Vlad Moisoiu, et al.
Biomarker Research
|
August 15, 2025
Targeting degradation of IKZF1 and IKZF3 through modulation of the E3 ligase substrates in the context of cellular therapies for multiple myeloma
David Kegyes, Anamaria Bancos, Adrian Bogdan Tigu, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 26) with videos related to
Sort By:
Page
of 3
Journal of Hematology & Oncology
|
June 7, 2022
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
David Kegyes, Catalin Constantinescu, Louise Vrancken, et al.
Critical Reviews in Oncology/Hematology
|
March 13, 2026
Integrating venetoclax-based targeted and/or immune therapies for chronic lymphocytic leukemia
David Kegyes, Ximena Muresan, Anamaria Bancos, et al.
Molecular Cancer Therapeutics
|
January 2, 2026
Proteolysis targeting chimeric-based technology in myeloma and lymphoma
Adrian Bogdan Tigu, Andrei Ivancuta, Ciprian Tomuleasa, et al.
Best Practice & Research. Clinical Haematology
|
September 7, 2025
Adoptive cellular therapies in multiple myeloma
David Kegyes, Bogdan Borlea, Marc Damian, et al.
Blood Reviews
|
June 8, 2023
Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma
David Kegyes, Diana Gulei, Rares Drula, et al.
Diagnostics (Basel, Switzerland)
|
September 28, 2024
"Lazarus Response" When Feto-Maternal Microchimerism Kicks in: Spontaneous Remission in Refractory Primary Mediastinal B Cell Lymphoma Following Twin Pregnancy
Radu Andrei Tomai, Sabina Iluta, Adrian Bogdan Tigu, et al.
Best Practice & Research. Clinical Haematology
|
September 7, 2025
Adoptive cellular therapies in non-Hodgkin lymphomas
David Kegyes, Bogdan Borlea, Marc Damian, et al.
Journal of Cellular and Molecular Medicine
|
February 10, 2026
Snapshot Look at Castleman Disease
Ciprian Jitaru, Natalia Zlampa, Delia Dima, et al.
Journal of Cellular and Molecular Medicine
|
March 5, 2025
SERS-Based Assessment of DNA Methylation for the Evaluation of Measurable Residual Disease in Acute Promyelocytic Leukaemia
Anamaria Bancos, Stefania D Iancu, Vlad Moisoiu, et al.
Biomarker Research
|
August 15, 2025
Targeting degradation of IKZF1 and IKZF3 through modulation of the E3 ligase substrates in the context of cellular therapies for multiple myeloma
David Kegyes, Anamaria Bancos, Adrian Bogdan Tigu, et al.
Page
of 3